FAST-FNA analysis on TNIKi-treated tumors surprisingly revealed that the administration of NCB or MBZ substantially increased the number of tumor-infiltrating CD8+ T cells at day 9 of treatment and, to a lesser extent, CD4+ T cells at earlier time point of TNIKi treatment (Figure 2; Figure S7, Supporting Information). Here, CD8A is linked to neoplasm.